IHC - CD 123

The test is performed on a tissue sample, typically obtained through a biopsy. The sample is then processed in a laboratory where it is stained with a dye that binds to the CD123 protein if present.

The risks associated with this test are primarily related to the biopsy procedure used to collect the tissue sample. These can include pain, bleeding, and infection at the biopsy site.

A positive result indicates that the CD123 protein is present in the tissue sample. This could suggest a certain type of blood cancer, such as hairy cell leukemia, acute myeloid leukemia, or blastic plasmacytoid dendritic cell neoplasm.

A negative result means that the CD123 protein was not detected in the tissue sample. This can help rule out certain types of blood cancers that overexpress the CD123 protein.

The turn-around time for the test is typically 7 to 10 days, but this can vary depending on the laboratory.

If you receive a positive result, your healthcare provider will guide you on the next steps. This may include further testing or treatment options.

Yes, there are no dietary restrictions for this test.

While the IHC - CD 123 test is primarily used in the context of certain blood cancers, variations in CD123 expression are also studied in other conditions, like autoimmune diseases. However, its utility in these areas is still under research.

Insurance coverage varies, so you'll need to check with your insurance provider to see if this test is covered.

No special preparation is needed for this test.

No, this test requires a tissue sample that must be collected and processed in a laboratory setting.

The test itself is not painful. However, the biopsy procedure to collect the tissue sample can cause some discomfort.

The quality of the tissue sample and the handling and processing of the sample can potentially impact the test results. It's crucial to have this test performed at a reliable laboratory.

There is no specific age limit for this test. The decision is based on the clinical need and the judgment of the healthcare provider.

The IHC - CD 123 test is considered a reliable method for detecting the CD123 protein. However, no test is 100% accurate, and results should always be interpreted in the context of the individual's symptoms and medical history.

If needed, this test can be performed during pregnancy. Any potential risks or considerations will be discussed by your healthcare provider.

This test requires a tissue sample, usually obtained via a biopsy.

Yes, the results of this test can help guide treatment decisions by providing information on the presence or absence of the CD123 protein, which is implicated in certain types of blood cancers.